Literature DB >> 9620606

Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter.

C Olsson1, E Michaëlsson, E Parra, U Pettersson, P A Lando, M Dohlsten.   

Abstract

In addition to the signals obtained by ligation of the TCR, T cells need additional, co-stimulatory signals to be activated. One such co-stimulatory signal is delivered when CD28 on T cells binds to CD80 or CD86 on antigen-presenting cells (APC). In the present study, we analyzed the ability of CD80 and CD86 to co-stimulate human T cells activated by superantigen. Using the Raji B cell lymphoma, which express similar levels of CD80 and CD86, it was found that T cell proliferation was mainly co-stimulated by CD80. To further characterize the consequences of this biased co-stimulatory dependency, we employed a well-defined system of transfected CHO cells expressing human MHC class II together with CD80, CD86 or CD80 and CD86. Proliferation of freshly prepared CD4+ T cells required the presence of either CD80 or CD86. However, IL-2 production reached only suboptimal levels in the presence of CD86 but optimal levels with CD80. To analyze IL-2 transcriptional activity in CD80 and CD86 co-stimulated T cells we used Jurkat T cells transfected with luciferase reporter gene constructs. CD80 induced higher levels of IL-2 promoter-enhancer activity compared to CD86. Furthermore, the activity of transcription factors regulating the IL-2 promoter-enhancer region including activation protein-1, CD28 response element and nuclear factor kappaB were 4-8 times higher after CD80 compared to CD86 ligation. Our results suggest that the eventual appearance of CD80 on recently activated CD86+ APC is important for the superinduction of IL-2 production and to support vigorous T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620606     DOI: 10.1093/intimm/10.4.499

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  CD28/CTLA-4 and CD80/CD86 families: signaling and function.

Authors:  J M Slavik; J E Hutchcroft; B E Bierer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases.

Authors:  Satyendra Singh; Ketan Kumar; Mamta Panda; Aryan Srivastava; Amit Mishra; Vijay Kumar Prajapati
Journal:  Mol Divers       Date:  2022-05-28       Impact factor: 2.943

4.  Human β Defensin-3 Increases CD86 Expression on Monocytes by Activating the ATP-Gated Channel P2X7.

Authors:  Anthony B Lioi; Brian M Ferrari; George R Dubyak; Aaron Weinberg; Scott F Sieg
Journal:  J Immunol       Date:  2015-09-28       Impact factor: 5.422

5.  Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis.

Authors:  Romana Meletta; Adrienne Müller Herde; Patrick Dennler; Eliane Fischer; Roger Schibli; Stefanie D Krämer
Journal:  EJNMMI Res       Date:  2016-01-04       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.